Poster

Impact of Treatment With TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA), at Different Stages of Schizophrenia: a Post Hoc Analysis

TV-46000 is an FDA-approved long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone that has been shown to reduce time to impending relapse in patients with schizophreni...

Kelli R. Franzenburg , PhD;

10/26/2023

Implementation of Exercise Reminders to Improve Symptoms of Clinical Depression

This poster is part of the requirement in fulfillment of a Doctor of Nursing Practice (DNP) degree at Rutgers University, School of Nursing. The purpose of the project is to improve the s...

Femi R. Omidire , APN, PHMNP-BC;

10/26/2023

Improvements in Cognitive and Physical Functioning Outcomes in Depressed Patients Treated with AXS-05 (Dextromethorphan-Bupropion): Results from the EVOLVE Open-Label, Long-Term Study

AXS-05 exhibited rapid and sustained improvements in cognitive and physical functioning in individuals with MDD who previously tried one or more prior antidepressants. This study also sho...

Shawn Alter , PhD;

10/26/2023

Improvements in Daytime Functioning With Lemborexant Treatment

Daytime impairment can be assessed by items 4-7 of the 7-item Insomnia Severity Index. Here we report the impact of lemborexant (LEM) versus placebo on shifts in daytime-function-specific...

Margaret Moline , PhD;

10/26/2023

Impact of AXS-05 (Dextromethorphan-Bupropion) on Patient-Reported Insomnia Symptoms: Results from the GEMINI Trial

In GEMINI, AXS-05, an oral NMDA receptor antagonist approved for MDD, showed significantly higher response rates (defined as 50% reduction in QIDS insomnia score) starting at Week 3 throu...

William Olsufka , PharmD;

10/26/2023

Impact of Fremanezumab Treatment on Disability Outcomes in Patients With Migraine and Major Depressive Disorder: Results of the UNITE Study

Depression is a prevalent comorbidity associated with migraine, and the bidirectional relationship between the two disorders can negatively impact quality of life (QoL). During the 12-wee...

Peter McAllister , MD;

10/26/2023

Healthcare Resource Utilization and Costs of Using Cariprazine as the First Versus Subsequent Adjunctive Therapy for Major Depressive Disorder

Adjunctive therapy with atypical antipsychotics is a treatment option for patients diagnosed with major depressive disorder and inadequate response to antidepressant monotherapy. This cla...

Nadia Nabulsi , MPH, PhD;

10/26/2023

Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder

This retrospective analysis of administrative claims data compared healthcare resource utilization 6 months before and after initiating a combination of olanzapine and samidorphan (OLZ/SA...

Hemangi Panchmatia , MSc;

10/26/2023

Huffing and Puffing with Olanzapine: Olanzapine-Induced Dyspnea

This case report demonstrates a relationship between Olanzapine and hyperventilation. Increased minute ventilation on the ventilator while on olanzapine therapy, lack of other causes of i...

Aung Sitt Naing , MD;

10/26/2023

Impact of Adjunctive Cariprazine on Quality of Life in Major Depressive Disorder: A Post Hoc Analysis

Patients with major depressive disorder often have reduced quality of life. A previous phase 3 trial showed cariprazine adjunctive to antidepressant therapy reduces depressive symptoms in...

Nadia Nabulsi , MPH, PhD;

10/26/2023